The effect of endoscopic gastric plication on portosystemic pressure gradient in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease

Abstract

Background The goals of therapy for patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease include weight loss and reduction of the portosystemic pressure gradient (PPG) to decrease the risk of hepatic decompensation. Endoscopic gastric plication (EGP) is an effective endoscopic weight loss procedure. This study aimed to assess the effect of EGP on PPG.

Methods In this prospective pilot study, patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease underwent endoscopic ultrasound-guided PPG measurement prior to and at 6 months following EGP. Primary outcomes were the change in PPG and proportion of patients experiencing ≥ 20 % reduction in PPG at 6 months. Secondary outcomes included percent total weight loss (TWL) and changes in noninvasive tests of fibrosis.

Results 20 patients were included. Baseline median body mass index and liver stiffness measurement were 40.2 kg/m² (range 30.1–56.7) and 14.7 kPa (range 8.2–36), respectively. At 6 months, median PPG decreased from 5.4 mmHg (range 0.7–19.6) to 1.8 mmHg (range 0.4–17.6) (P = 0.002), with 79 % (11/14) experiencing ≥ 20 % reduction. Patients experienced 12.5 % (6.5 %–26.1 %) TWL (P < 0.001) at 6 months, with 89 % (17/19) achieving ≥ 7 % and 68 % (13/19) achieving ≥ 10 % TWL. There were significant improvements in noninvasive tests of fibrosis.

Conclusion EGP appeared to be effective at reducing PPG in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease.

Publication History

Received: 16 December 2022

Accepted after revision: 02 August 2023

Accepted Manuscript online:
02 August 2023

Article published online:
10 November 2023

• References

• 1 Younossi Z, Anstee QM, Marietti M. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018; 15: 11-20
• 2 Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L. et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015; 149: 367-378.e5
• 3 Katsagoni CN, Papatheodoridis GV, Ioannidou P. et al. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial. Br J Nutr 2018; 120: 164-175
• 4 Berzigotti A, Albillos A, Villanueva C. et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study. Hepatology 2017; 65: 1293-1305
• 5 Jirapinyo P, Thompson CC. Endoscopic bariatric and metabolic therapies: surgical analogues and mechanisms of action. Clin Gastroenterol Hepatol 2017; 15: 619-630
• 6 Jirapinyo P, Thompson CC. Obesity primer for the practicing gastroenterologist. Am J Gastroenterol 2021; 116: 918-934
• 7 Hedjoudje A, Abu Dayyeh BK, Cheskin LJ. et al. Efficacy and safety of endoscopic sleeve gastroplasty: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2020; 18: 1043-1053.e4
• 8 Sharaiha RZ, Hajifathalian K, Kumar R. et al. Five-year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity. Clin Gastroenterol Hepatol 2021; 19: 1051-1057.e2
• 9 Jirapinyo P, Thompson CC. A comparison of distal POSE techniques for the treatment of obesity. Gastrointest Endosc 2022;
• 10 Jirapinyo P, Zucker SD, Thompson CC. Regression of hepatic fibrosis following endoscopic gastric plication in nonalcoholic fatty liver disease. Am J Gastroenterol 2023; 118: 983-990
• 11 Mózes FE, Lee JA, Selvaraj EA. et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut 2022; 71: 1006-1019
• 12 Wong VW-S, Vergniol J, Wong GL-H. et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-462
• 13 D’Amico G, Garcia-Pagan JC, Luca A. et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006; 131: 1611-1624
• 14 Petroff D, Blank V, Newsome PN. et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol 2021; 6: 185-198
• 15 Pennisi G, Enea M, Pandolfo A. et al. AGILE 3+ score for the diagnosis of advanced fibrosis and for predicting liver-related events in NAFLD. Clin Gastroenterol Hepatol 2022;
• 16 Newsome PN, Sasso M, Deeks JJ. et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 2020; 5: 362-373
• 17 Cotton PB, Eisen GM, Aabakken L. et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010; 71: 446-454
• 18 Ferrusquía-Acosta J, Bassegoda O, Turco L. et al. Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis. J Hepatol 2021; 74: 811-818
• 19 Rinella ME, Dufour J-F, Anstee QM. et al. Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study. J Hepatol 2022; 76: 536-548
• 20 Loomba R, Sanyal AJ, Kowdley KV. et al. Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis. Gastroenterology 2019; 156: 88-95.e5
• 21 Chin JL, Pavlides M, Moolla A. et al. Non-invasive markers of liver fibrosis: adjuncts or alternatives to liver biopsy?. Front Pharmacol 2016; 7: 159